• September 18, 2020

Synaffix Sees Competitive Early In Vivo Data from ADCs Based on Proprietary Exatecan Linker-Payload - Odessa American: Business

e-Edition Subscribe

Synaffix Sees Competitive Early In Vivo Data from ADCs Based on Proprietary Exatecan Linker-Payload

Print
Font Size:
Default font size
Larger font size

Posted: Wednesday, September 16, 2020 1:01 am | Updated: 1:34 am, Wed Sep 16, 2020.

AMSTERDAM--(BUSINESS WIRE)--Sep 16, 2020--

Synaffix B.V., a biotechnology company enabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, based on proprietary GlycoConnect™, HydraSpace™ and toxSYN™ technology platforms, announces promising findings from its latest in vivo benchmarking study.

In this mouse BT-474 xenograft study, trastuzumab-based ADCs prepared using Synaffix’s proprietary SYNtecan E™ linker-payload demonstrated an efficacy profile equivalent to deruxtecan-based ADCs. SYNtecan E™ is an exatecan-based linker-payload that contains the HydraSpace™ polar spacer technology, a conventional dipeptide cleavable linker and is conjugated, in this study, to the native antibody glycan using GlycoConnect™. Deruxtecan is the linker-payload used in Enhertu®, the FDA-approved ADC indicated for previously treated, HER-2 positive unresectable or metastatic breast cancer.

Following just a single dose, both HER-2-targeting ADCs, which have the same drug-to-antibody ratio (DAR) and administered at the same dose level, achieved complete tumor regression.

A poster of the data will be presented at the World ADC Digital conference on Thursday, 17 September 2020 at 3:30p-4:00p EDT.

Floris van Delft, CSO of Synaffix said:

“Given the recent clinical and commercial success observed with deruxtecan-based ADCs, we have been very excited with our first data for ADCs with the same mechanism of action.”

“Exatecan mesylate has completed Phase 3 studies as a single agent already and comes with a well-understood toxicology profile. That said, its relatively challenging biophysical properties have likely contributed to limited exploration within the ADC context to date, despite its high potency and putative bystander killing potential. We have resolved the ADC aggregation issue by combining exatecan with our highly polar HydraSpace™ technology, providing highly stable and efficacious ADCs. We look forward to presenting further data on this new linker-payload and introducing it to our collaborators in due course.”

Deruxtecan and SYNtecan E™ both belong to the family of camptothecins and are potent DNA topoisomerase 1 inhibitors that release DXd and exatecan as the active catabolite respectively.

SYNtecan E™ represents one of multiple options within the toxSYN™ linker-payload platform, which spans multiple mechanisms of action and can be evaluated in combination with GlycoConnect™ and HydraSpace™ technologies. This consolidated ADC platform enables any company with an antibody to rapidly co-discover an ADC with Synaffix and then develop and market the resulting ADC as part of its own pipeline under a license agreement.

Notes to Editors

About GlycoConnect™ and HydraSpace™

The clinical-stage GlycoConnect™ and HydraSpace™ technologies enable best-in-class ADCs lacking effector function with significantly enhanced efficacy and tolerability. GlycoConnect™ is the conjugation technology that exploits the native antibody glycan for site-specific and stable payload attachment, tailored to DAR1, DAR2 or DAR4 format. HydraSpace™ is a compact and highly polar spacer technology that accommodates hydrophobic payloads and further enhances therapeutic index. These technologies can be applied directly to any existing antibody without any protein sequence engineering and are compatible with all ADC payload classes.

The growing experience of Synaffix and its collaboration partners continues to confirm the ability of GlycoConnect™ and HydraSpace™ to consistently generate ADCs with enhanced therapeutic index compared to the three major clinical-stage conjugation technologies.

About Synaffix B.V.

Synaffix B.V. is a biotechnology company that enables best-in-class ADC product candidates using its clinical-stage, site-specific ADC technology platform. In addition to GlycoConnect™ and the ADC-enhancing HydraSpace™ technology, the extension of the platform with toxSYN™ payloads provides a fully complementary technology platform that enables any company with an antibody to develop proprietary ADC products.

The Synaffix platform comes with an IND-ready CMC package to support a rapid timeline to the clinic. Granted patents covering Synaffix’ technology provide end-to-end protection of the platform technology as well as of the resulting products through at least 2035. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with Shanghai Miracogen, Mersana Therapeutics and ADC Therapeutics.

Synaffix is backed by a top tier, European, life science-focused investor syndicate that includes Aravis, BioGeneration Ventures, BOM Capital and M Ventures.

For more information, please visit the website at www.synaffix.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200915005624/en/

CONTACT: Synaffix BV

Anthony DeBoer

Director, Business Development

bd@synaffix.comInstinctif Partners

Melanie Toyne-Sewell / Phil Marriage

Tel: +44 207 457 2020

synaffix@instinctif.com

KEYWORD: NETHERLANDS EUROPE

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH

SOURCE: Synaffix B.V.

Copyright Business Wire 2020.

PUB: 09/16/2020 02:00 AM/DISC: 09/16/2020 02:00 AM

http://www.businesswire.com/news/home/20200915005624/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Sunny
60°
Humidity: 87%
Winds: NNE at 6mph
Feels Like: 59°

Your Extended Forecast

Tomorrow

weather
High 84°/Low 57°
Sunshine. Highs in the mid 80s and lows in the upper 50s.

saturday

weather
High 83°/Low 56°
Abundant sunshine. Highs in the low 80s and lows in the mid 50s.

sunday

weather
High 84°/Low 54°
Sunny. Highs in the mid 80s and lows in the mid 50s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.